ALLOGENE THERAPEUTICS INC holding history
As of Nov. 6, 2026 (UTC)
| March 31, 2025 | 4,931,840 | $7,200,486 | 0.01% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | May 9, 2025 |
| June 30, 2025 | 5,719,140 | $6,462,628 | 0.01% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Aug. 11, 2025 |
| Sept. 30, 2025 | 7,079,308 | $8,778,342 | 0.01% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Nov. 12, 2025 |
| Dec. 31, 2025 | 8,139,840 | $11,151,581 | 0.01% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Feb. 11, 2026 |
| March 31, 2026 | 8,379,840 | $20,446,810 | 0.02% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | May 11, 2026 |
| June 30, 2026 | 13,123,440 | $27,296,756 | 0.02% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Aug. 14, 2026 |
6 rows · Sort by column; scroll horizontally for more.
No rows match these filters.
Schedule 13G disclosures
No verified related disclosures are included in this freeze.
About reported holdings
13F reports quarter-end securities, excluding cash and shorts. Position changes do not establish trades, motives or returns; portfolio weights use disclosed 13F value.